Table 1.
Baseline patient characteristics and composition of OBR
| Characteristics | Values |
|---|---|
| Age, years | 45 (40–52) |
| Male, n (%) | 92 (86) |
| Number of previous regimens | 6 (4–7) |
| Years of treatment experience | 12 (9–17) |
| Baseline HIV-1 plasma viral load, copies/mL | 23,100 (4512–75,772) |
| Baseline HIV-1 RNA >100,000 copies/mL, n (%) | 20 (18.7) |
| Baseline CD4+ cell counts (cells/μL) | 244 (128–404) |
| Baseline CD4+ cells count <200 cells/μL, n (%) | 40 (37.4) |
| GSS for OBR | 1.25 (1.0–2.0) |
| DRV in regimen, n (%) | 102 (95) |
| TDF in regimen, n (%) | 66 (61.7) |
| ETV in regimen, n (%) | 28 (26.2) |
| ENF in regimen, n (%) | 13 (12.1) |
| EFV in regimen, n (%) | 8 (7.5) |
| MVC in regimen, n (%) | 8 (7.5) |
| Stanford score for TDF | 55 (25–65) |
| Stanford score for ETV | 0 (0–30) |
| Stanford score for DRV | 15 (0–20) |
| Number of PI RAMs, for DRV | 1 (1–2) |
| Number of PI RAMs, non-DRV RAMs | 4 (3–6) |
| Glucose (mg/dL) | 85 (78–91) |
| Creatinine (mg/dL) | 0.85 (0.70–1.0) |
| ALT (IU/dL) | 30 (19–48) |
| Total cholesterol (mg/dL) | 166 (137–200) |
| Triglycerides (mg/dL) | 193 (137–264) |
Values are n (%) or median (IQR)
ALT alanine aminotransferase, DRV darunavir, GSS genotypic sensitivity score, EFV efavirenz, ENF enfuvirtide, ETV etravirine, IQR interquartile range, MVC maraviroc, OBR optimized background regimen, PI protease inhibitor, RAM resistance-associated mutation, TDF tenofovir